Sulfhydryl-mediated redox signaling in inflammation: role in neurodegenerative diseases

Archives of Toxicology

Volumn 89, Issue 9, 2015, Pages 1439-1467

  Gorelenkova Miller, Olga ^a   Mieyal, John J ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

Inflammation; Neurodegeneration; Neuroinflammation; S glutathionylation; S nitrosylation; Sulfhydryl

Indexed keywords

4 HYDROXYNONENAL; ACETYLCYSTEINE; ACTIN; ALPHA SYNUCLEIN; CALGRANULIN B; CRYOPYRIN; CYSTEINE; GLUTATHIONE TRANSFERASE ALPHA; HEME OXYGENASE 1; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 6; MINOCYCLINE; MYELOID DIFFERENTIATION FACTOR 88; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; STAT3 PROTEIN; SUPEROXIDE; SUPEROXIDE DISMUTASE; SYNAPTOTAGMIN I; THIOL DERIVATIVE; THIOREDOXIN; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; PROTEIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CELL SURVIVAL; CHEMICAL MODIFICATION; CYTOKINE PRODUCTION; GLUTATHIONE METABOLISM; GLUTATHIONYLATION; HUMAN; HUNTINGTON CHOREA; INFLAMMATION; MULTIPLE SCLEROSIS; NERVE CELL DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NITROSYLATION; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CHEMISTRY; DEGENERATIVE DISEASE; METABOLISM; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN PROCESSING;

ANIMALS; CYSTEINE; HUMANS; INFLAMMATION; NEURODEGENERATIVE DISEASES; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEINS; SIGNAL TRANSDUCTION; SULFHYDRYL COMPOUNDS;

EID: 84940598646     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-015-1496-7     Document Type: Review

References (205)

1. Adachi T et al (2004) S-glutathiolation by peroxynitrite activates SERCA during arterial relaxation by nitric oxide. Nat Med 10(11):1200–1207
2. Aesif SW, Janssen-Heininger YMW, Reynaert NL (2010) Protocols for the detection of s-glutathionylated and s-nitrosylated proteins in situ, 1st edn. Elsevier, Amsterdam
3. Aesif SW et al (2011) Ablation of glutaredoxin-1 attenuates lipopolysaccharide-induced lung inflammation and alveolar macrophage activation. Am J Respir Cell Mol Biol 44(4):491–499
4. Anand A, Thakur K, Gupta PK (2013) ALS and oxidative stress: the neurovascular scenario. Oxid Med Cell Longev 2013:635831. doi:10.1155/2013/635831
5. Anneser J et al (2004) Glial proliferation and metabotropic glutamate receptor expression in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 63(8):831–840
6. Aoyama K, Nakaki T (2013) Impaired glutathione synthesis in neurodegeneration. Int J Mol Sci 14(10):21021–21044
7. Appel SH et al (2011) The microglial-motoneuron dialogue in ALS. Acta myologica: myopathies and cardiomyopathies: official journal of the Mediterranean Society of Myology/edited by the Gaetano Conte Academy for the study of striated muscle diseases 30(1):4–8
8. Akira S, Takeda K (2004) Toll-like receptor signalling. Nat Rev Immunol 4(7):499–511
9. Bansal G et al (2013) IL-22 activates oxidant signaling in pulmonary vascular smooth muscle cells. Cell Signal 25(12):2727–2733
10. Bonizzi G, Karin M (2004) The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25(6):280–288
11. Bradford J et al (2010) Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice. J Biol Chem 285(14):10653–10661
12. Breidert T et al (2002) Protective action of the peroxisome proliferator-activated receptor-γ agonist pioglitazone in a mouse model of Parkinson’s disease. J Neurochem 82(3):615–624. doi:10.1046/j.1471-4159.2002.00990.x
13. Brooks BR (2009) Managing amyotrophic lateral sclerosis: slowing disease progression and improving patient quality of life. Ann Neurol 65(Suppl 1):S17–S23
14. Browne SE, Beal MF (2006) Oxidative damage in Huntington’s disease pathogenesis. Antioxid Redox Signal 8(11–12):2061–2073
15. Butterfield DA, Swomley AM, Sultana R (2013) Amyloid β-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression. Antioxid Redox Signal 19(8):823–835
16. Butturini E et al (2013) Mild oxidative stress induces S-glutathionylation of STAT3 and enhances chemosensitivity of tumoural cells to chemotherapeutic drugs. Free Radic Biol Med 65:1322–1330
17. Butturini E et al (2014) S-glutathionylation at Cys328 and Cys542 impairs STAT3 phosphorylation. ACS Chem Biol 9(8):1885–1893
18. Carvalho AN et al (2014) Glutathione in multiple sclerosis: more than just an antioxidant? Mult Scler (Houndmills, Basingstoke, England) 20(11):1425–1431
19. Casoli T et al (2010) Peripheral inflammatory biomarkers of Alzheimer’s disease: the role of platelets. Biogerontology 11(5):627–633
20. Chantzoura E et al (2010) Glutaredoxin-1 regulates TRAF6 activation and the IL-1 receptor/TLR4 signalling. Biochem Biophys Res Commun 403(3–4):335–339
21. Chung S et al (2010) Glutaredoxin 1 regulates cigarette smoke-mediated lung inflammation through differential modulation of IκB kinases in mice: impact on histone acetylation. Am J Physiol Lung Cell Mol Physiol 299(2):L192–L203
22. Chung J-Y et al (2013) Elevated TRAF2/6 expression in Parkinson’s disease is caused by the loss of Parkin E3 ligase activity. Lab Investig 93(6):663–676
23. Collins LM et al (2012) Contributions of central and systemic inflammation to the pathophysiology of Parkinson’s disease. Neuropharmacology 62(7):2154–2168
24. Conrad M et al (2013) Glutathione and thioredoxin dependent systems in neurodegenerative disease: What can be learned from reverse genetics in mice. Neurochem Int 62:738–749
25. Cruz CM et al (2007) ATP activates a reactive oxygen species-dependent oxidative stress response and secretion of proinflammatory cytokines in macrophages. J Biol Chem 282(5):2871–2879
26. Cudkowicz ME et al (2006) Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol 60(1):22–31
27. Czirr E, Wyss-Coray T (2012) The immunology of neurodegeneration. J Clin Invest 122(4):1156–1163
28. D’Ambrosi N et al (2014) Rac1 at the crossroad of actin dynamics and neuroinflammation in Amyotrophic Lateral Sclerosis. Front Cell Neurosci 8:279
29. Dalle-Donne I et al (2002) Reversible S-glutathionylation of Cys374 regulates actin filament formation by inducing structural changes in the actin molecule. Free Radic Biol Med 34(1):23–32
30. Deleidi M, Gasser T (2013) The role of inflammation in sporadic and familial Parkinson’s disease. Cell Mol Life Sci CMLS 70(22):4259–4273
31. Derudder E et al (2003) RelB/p50 dimers are differentially regulated by tumor necrosis factor-alpha and lymphotoxin-beta receptor activation: critical roles for p100. J Biol Chem 278(26):23278–23284
32. Diamant G, Dikstein R (2013) Transcriptional control by NF-κB: elongation in focus. Biochim et biophys Acta 1829:937–945
33. Díaz-amarilla P et al (2011) Phenotypically aberrant astrocytes that promote motoneuron damage in a model of inherited amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 108(44):18126–18131
34. Dimmeler BS et al (1997) suppression of apoptosis by nitric oxide via inhibition of interleukin-1b–converting enzyme (ICE)-like and cysteine protease protein (CPP)-32—like proteases. J Exp Med 185(4):601–607
35. Doens D, Fernández PL (2014) Microglia receptors and their implications in the response to amyloid β for Alzheimer’s disease pathogenesis. J Neuroinflammation 11:48
36. Dzamko N et al (2012) The IkappaB kinase family phosphorylates the Parkinson’s disease kinase LRRK2 at Ser935 and Ser910 during toll-like receptor signaling. PloS One 7(6):e39132
37. Edgeworth J et al (1991) Identification of p8, 14 as a highly abundant heterodimeric calcium binding protein complex of myeloid cells. J Biol Chem 266(12):7706–7713
38. Elliott JM et al (2009) Crystal structure of procaspase-1 zymogen domain reveals insight into inflammatory caspase autoactivation. J Biol Chem 284(10):6546–6553
39. Estelle R, Parain K, Chantal J (2002) Role of TNF-α receptors in mice intoxicated with the parkinsonian toxin MPTP. Exp Neurol 192:183–192
40. Evans MC et al (2013) Inflammation and neurovascular changes in amyotrophic lateral sclerosis. Mol Cell Neurosci 53:34–41
41. Ferger B et al (2004) Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum. J Neurochem 89(4):822–833
42. Fiaschi T et al (2006) Redox regulation of beta-actin during integrin-mediated cell adhesion. J Biol Chem 281(32):22983–22991
43. Findlay VJ et al (2006) A novel role for human sulfiredoxin in the reversal of glutathionylation. Cancer Res 66(13):6800–6806
44. Finn NA, Kemp ML (2012) Pro-oxidant and antioxidant effects of N-acetylcysteine regulate doxorubicin-induced NF-kappa B activity in leukemic cells. Mol Biosys 8(2):650–662
45. Foster MW, Hess DT, Stamler JS (2009) Protein S-nitrosylation in health and disease: a current perspective. Trends Mol Med 15(9):391–404
46. Gallogly MM, Mieyal JJ (2007) Mechanisms of reversible protein glutathionylation in redox signaling and oxidative stress. Curr Opin Pharmacol 7(4):381–391
47. Gallogly MM, Starke DW, Mieyal JJ (2009) Mechanistic and kinetic details of catalysis of thiol-disulfide exchange by glutaredoxins and potential mechanisms of regulation. Antioxidants & redox signaling 11(5):1059–1081
48. Gandhi S, Abramov AY (2012) Mechanism of oxidative stress in neurodegeneration. Oxid Med Cell Longev 2012:428010–428021
49. Gao F et al (2013a) Rotenone directly induces BV2 cell activation via the p38 MAPK pathway. PloS One 8(8):e72046
50. Gao X-H et al (2013b) Aging-dependent changes in rat heart mitochondrial glutaredoxins—implications for redox regulation. Redox Biol 1(1):586–598
51. Garcia-Garcia A et al (2012) Thiol-redox signaling, dopaminergic cell death, and Parkinson’s disease. Antioxid Redox Signal 17(12):1764–1784
52. Geetha T et al (2012) TRAF6 and p62 inhibit amyloid β-induced neuronal death through p75 neurotrophin receptor. Neurochem Int 61(8):1289–1293
53. Gilgun-Sherki Y, Melamed E, Offen D (2006) Anti-Inflammatory drugs in the treatment of neurodegenerative diseases: current state. Curr Pharm Des 12(27):3509–3519
54. Goyette J, Geczy CL (2011) Inflammation-associated S100 proteins: new mechanisms that regulate function. Amino Acids 41(4):821–842
55. Greiner R et al (2013) Polysulfides link H2S to protein thiol oxidation. Antioxid Redox Signal 19(15):1749–1765
56. Griffin WST (2008) Perispinal etanercept: potential as an Alzheimer therapeutic. J Neuroinflammation 5:3
57. Grilli M et al (1995) Identification and characterization of a B/Rel binding site in the regulatory region of the amyloid precursor protein gene. J Neurosci 270(45):26774–26777. doi:10.1074/jbc.270.45.26774
58. Group AR et al (2008) Cognitive function over time in the Alzheimer’s disease anti-inflammatory prevention trial (ADAPT). Arch Neurol 65(7):896–905
59. Grumbach IM et al (2005) A negative feedback mechanism involving nitric oxide and nuclear factor kappa-B modulates endothelial nitric oxide synthase transcription. J Mol Cell Cardiol 39(4):595–603
60. Gupta V, Carroll KS (2014) Sulfenic acid chemistry, detection and cellular lifetime. Biochim Biophys Acta 2:847–875
61. Guzmán-Martínez L, Farías GA, Maccioni RB (2012) Emerging noninvasive biomarkers for early detection of Alzheimer’s disease. Arch Med Res 43(8):663–666
62. Gveric D et al (1998) Transcription factor NF-kappaB and inhibitor I kappaBalpha are localized in macrophages in active multiple sclerosis lesions. J Neuropathol Exp Neurol 57(2):168–178
63. Hall CN, Garthwaite J (2009) What is the real physiological NO concentration in vivo? Nitric Oxide 21:92–103
64. Hall J et al (2014) Biomarkers of vascular risk, systemic inflammation and microvascular pathology and neuropsychiatric symptoms in Alzheimer’s disease. J Alzheimers Dis 35(2):363–371
65. Halle A et al (2008) The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 9(8):857–865
66. Halliwell B (2006) Oxidative stress and neurodegeneration: Where are we now? J Neurochem 97(6):1634–1658
67. Halloran M, Parakh S, Atkin JD (2013) The role of s-nitrosylation and s-glutathionylation of protein disulphide isomerase in protein misfolding and neurodegeneration. Int J Cell Biol 2013:797914. doi:10.1155/2013/797914
68. Harms AS et al (2011) Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson’s disease. Mol Ther 19(1):46–52
69. Harraz MM et al (2008) SOD1 mutations disrupt redox-sensitive Rac regulation of NADPH oxidase in a familial ALS model. J Clin Investig 118(2):659–670
70. Heneka MT et al (2013) NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature 493(7434):674–678
71. Hernandez-Cuellar E et al (2012) Cutting edge: nitric oxide inhibits the NLRP3 inflammasome. J Immunol (Baltimore, Md.: 1950) 189(11):5113–5117
72. Hess DT et al (2005) Protein S-nitrosylation: purview and parameters. Nat Rev Mol Cell Biol 6(2):150–166
73. Hilliard B et al (1999) Experimental autoimmune encephalomyelitis in NF-kappa B-deficient mice: roles of NF-kappa B in the activation and differentiation of autoreactive T cells. J Immunol 163(5):2937–2943
74. Ho Y et al (2008) Targeted disruption of the glutaredoxin 1 gene does not sensitize adult mice to tissue injury induced by ischemia/reperfusion and hyperoxia. Free Radic Biol Med 43(9):1299–1312
75. Hollingworth P et al (2011) Alzheimer’s disease genetics: current knowledge and future challenges. Int J Geriatr Psychiatry 26(8):793–802
76. Huang Y et al (2005) NF-kappaB precursor, p105, and NF-kappaB inhibitor, IkappaBgamma, are both elevated in Alzheimer disease brain. Neurosci Lett 373(2):115–118
77. Huh SH et al (2011) Ethyl pyruvate rescues nigrostriatal dopaminergic neurons by regulating glial activation in a mouse model of Parkinson’s disease. J Immunol (Baltimore, Md.: 1950) 187(2):960–969
78. Hull J et al (2015) Regional Increase in the expression of the BCAT proteins in Alzheimer’s disease brain: implications in glutamate toxicity. J Alzheimers Dis. doi:10.3233/JAD-142970
79. Ii M et al (1996) beta-Amyloid protein-dependent nitric oxide production from microglial cells and neurotoxicity. Brain Res 720(1–2):93–100
80. Imai Y, Kohsaka S (2002) Intracellular signaling in M-CSF-induced microglia activation: role of Iba1. Glia 40(2):164–174
81. Into T et al (2008) Regulation of MyD88-dependent signaling events by S nitrosylation retards toll-like receptor signal transduction and initiation of acute-phase immune responses. Mol Cell Biol 28(4):1338–1347
82. Ishibashi K et al (2006) Absence of synaptophysin near cortical neurons containing oligomer Abeta in Alzheimer’s disease brain. J Neurosci Res 636(April):632–636
83. Jaffrey SR et al (2001) Protein S-nitrosylation: a physiological signal for neuronal nitric oxide. Nat Cell Biol 3(February):193–197
84. Johnson WM, Wilson-Delfosse AL, Mieyal JJ (2012) Dysregulation of glutathione homeostasis in neurodegenerative diseases. Nutrients 4(10):1399–1440
85. Johri A, Beal MF (2012) Antioxidants in Huntington’s disease. Biochim et Biophys Acta 5:664–674
86. Jung C et al (2001) Synthetic superoxide dismutase/catalase mimetics reduce oxidative stress and prolong survival in a mouse amyotrophic lateral sclerosis model. Neurosci Lett 304(3):157–160
87. Kanwar J (2005) Anti-inflammatory immunotherapy for multiple sclerosis/experimental autoimmune encephalomyelitis (EAE) disease. Curr Med Chem 12(25):2947–2962
88. Kashfi K (2012) Nitric oxide–releasing hybrid drugs target cellular processes through S-nitrosylation. For Immunopathol Dis Therap 3(2):97–108
89. Katsuyama K, Hirata Y (2001) A pyrrolidinone derivative inhibits cytokine-induced iNOS expression and NF-KB activation by preventing phosphorylation and degradation of IκB-α. J Biochem 129(4):585–591
90. Katsuyama K et al (1998) NO inhibits cytokine-induced iNOS expression and NF-kB activation by interfering with phosphorylation and degradation of IkB-a. Arterioscler Thromb Vasc Biol 18(11):1796–1802. doi:10.1161/01.ATV.18.11.1796
91. Kawamata J, Shimohama S (2011) Stimulating nicotinic receptors trigger multiple pathways attenuating cytotoxicity in models of Alzheimer’s and Parkinson’s diseases. J Alzheimers Dis 24(Suppl 2):95–109
92. Kelleher ZT et al (2007) NOS2 regulation of NF-kappaB by S-nitrosylation of p65. J Biol Chem 282(42):30667–30672
93. Kelleher ZT et al (2014) Thioredoxin-mediated denitrosylation regulates cytokine-induced nuclear factor κB (NF-κB) activation. J Biol Chem 289(5):3066–3072
94. Kenchappa RS et al (2004) Estrogen and neuroprotection: higher constitutive expression of glutaredoxin in female mice offers protection against MPTP-mediated neurodegeneration. FASEB J 18(10):1102–1104
95. Khoshnan A, Patterson PH (2011) The role of IκB kinase complex in the neurobiology of Huntington’s disease. Neurobiol Dis 43(2):305–311
96. Kil IS, Kim SY, Park J-W (2008) Glutathionylation regulates IkappaB. Biochem Biophys Res Commun 373(1):169–173
97. Kim Y et al (1998) Nitric oxide prevents IL-1β and IFN-γ-inducing factor (IL-18) release from macrophages by inhibiting caspase-1(IL-1β-converting enzyme). J Immunol 161:4122–4128
98. Kim N-H et al (2007) Auranofin blocks interleukin-6 signalling by inhibiting phosphorylation of JAK1 and STAT3. Immunology 122(4):607–614
99. Kim J, Won JS, Singh AK, Sharma AK, Singh I (2014) STAT3 regulation by S-nitrosylation: implication for inflammatory disease. Antioxid Redox Signal 20(16):2514–2527
100. Kordula T et al (2000) Mechanism of interleukin-1- and tumor necrosis factor alpha-dependent regulation of the alpha 1-antichymotrypsin gene in human astrocytes. J Neurosci 20(20):7510–7516
101. Kwak Y-D et al (2010) NO signaling and S-nitrosylation regulate PTEN inhibition in neurodegeneration. Mol Neurodegener 5:49
102. Kwan W et al (2012) Mutant huntingtin impairs immune cell migration in Huntington disease. J Clin Investig 122(12):4737–4747
103. Latz E, Xiao TS, Stutz A (2013) Activation and regulation of the inflammasomes. Nat Rev Immunol 13(6):397–411
104. Leng A et al (2005) Tumor necrosis factor-alpha receptor ablation in a chronic MPTP mouse model of Parkinson’s disease. Neurosc Lett 375(2):107–111
105. Lian K-C et al (2010) Dual mechanisms of NF-kappaB inhibition in carnosol-treated endothelial cells. Toxicol Appl Pharmacol 245(1):21–35
106. Liao B-C et al (2010) The glutaredoxin/glutathione system modulates NF-kappaB activity by glutathionylation of p65 in cinnamaldehyde-treated endothelial cells. Toxicological sciences: an official journal of the Society of Toxicology 116(1):151–163
107. Lim SY et al (2010) S-glutathionylation regulates inflammatory activities of S100A9. J Biol Chem 285(19):14377–14388
108. Lim SY et al (2013) S-nitrosylated S100A8: novel anti-inflammatory properties. J Immunol 181:5627–5636
109. 2-treated endothelial cells. Free Rad Biol Med 52(9):1844–1853
110. Lo Conte M, Carroll KS (2013) The chemistry of thiol oxidation and detection. In: Jakob U, Reichmann D (eds) Oxidative stress and redox regulation. Springer, Berlin, pp 1–42
111. Lu C et al (2013) S-sulfhydration/desulfhydration and S-nitrosylation/denitrosylation: a common paradigm for gasotransmitter signaling by H2S and NO. Methods 62(2):177–181
112. Martínez-Ruiz A, Lamas S (2007) Signalling by NO-induced protein S-nitrosylation and S-glutathionylation: convergences and divergences. Cardiovasc Res 75(2):220–228
113. Mattson MP, Camandola S (2001) NF-κ B in neuronal plasticity and neurodegenerative disorders. J Clin Investig 107(3):247–254
114. McCoy MK, Tansey MG (2008) TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation 5:45
115. McCoy MK et al (2006) Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson’s disease. J Neurosci 26(37):9365–9375
116. McGeer PL, Rogers J, McGeer EG (2006) Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. J Alzheimers Dis 9(3 Suppl):271–276
117. Meissner F, Molawi K, Zychlinsky A (2008) Superoxide dismutase 1 regulates caspase-1 and endotoxic shock. Nat Immunol 9(8):866–872
118. Mieyal JJ, Chock PB (2012) Posttranslational modification of cysteine in redox signaling and oxidative stress: focus on S-glutathionylation. Antioxid Redox Signal 16(6):471–475
119. Mieyal JJ et al (2008) Molecular mechanisms and clinical implications of reversible protein S-glutathionylation. Antioxid Redox Signal 10(11):1941–1988
120. Mitchell RM et al (2009) A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis. Neurology 72(1):14–19
121. Mogi M et al (1994) Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 165(1–2):208–210
122. Monson NL et al (2014) Elevated CNS inflammation in patients with preclinical Alzheimer’s disease. J Cereb Blood Flow Metab 34(1):30–33
123. Mowbray M et al (2008) Topically applied nitric oxide induces T-lymphocyte infiltration in human skin, but minimal inflammation. J Investig Dermatol 128(2):352–360
124. Murata H et al (2003) Glutaredoxin exerts an antiapoptotic effect by regulating the redox state of Akt. J Biol Chem 278(50):50226–50233
125. Murphy MP (2012) Mitochondrial thiols in antioxidant protection and redox signaling: distinct roles for glutathionylation and other thiol modifications. Antioxid Redox Signal 16(6):476–495
126. Mustafa AK et al (2009) H2S signals through protein S-sulfhydration. Sci Signal 2(96):72
127. Nikitovic D, Holmgren A (1996) S-Nitrosoglutathione is cleaved by the thioredoxin system with liberation of glutathione and redox regulating nitric oxide. J Biol Chem 271(32):19180–19185. doi:10.1074/jbc.271.32.19180
128. Nolin JD et al (2014) The glutaredoxin/S-glutathionylation axis regulates interleukin-17A-induced proinflammatory responses in lung epithelial cells in association with S-glutathionylation of nuclear factor κ B family proteins. Free Rad Biol Med 73:143–153
129. Numajiri N et al (2011) On-off system for PI3-kinase-Akt signaling through S-nitrosylation of phosphatase with sequence homology to tensin (PTEN). Proc Natl Acad Sci U S A 108(25):10349–10354
130. Oeckinghaus A, Hayden MS, Ghosh S (2011) Crosstalk in NF-κB signaling pathways. Nat Immunol 12(8):695–708
131. Olmos G, Lladó J (2014) Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity. Mediat Inflamm 2014:861231. doi:10.1155/2014/861231
132. Ortiz GG et al (2013) Immunology and oxidative stress in multiple sclerosis: clinical and basic approach. Clin Dev Immunol 2013:708659
133. Ozawa K et al (2013) S-nitrosylation regulates mitochondrial quality control via activation of parkin. Sci Rep 3:2202
134. Pantano C et al (2006) Redox-sensitive kinases of the nuclear factor-kB signaling pathway. Antioxid Redox Signal 8(9,10):1791–1806
135. Park JW, Mieyal JJ, Rhee SG, Chock PB (2009) Deglutathionylation of 2-Cys peroxiredoxin is specifically catalyzed by sulfiredoxin. J Biol Chem 284(35):23364–23374
136. Pei D-S, Sun Y-F, Song Y-J (2009) S-nitrosylation of PTEN invovled in ischemic brain injury in rat hippocampal CA1 region. Neurochem Res 34(8):1507–1512
137. Peng H, Libby P, Liao J (1995) Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B. J Biol Chem 270(23):14214–14219
138. Pennisi G et al (2011) Redox regulation of cellular stress response in multiple sclerosis. Biochem Pharmacol 82(10):1490–1499
139. Perry VH, Cunningham C, Holmes C (2007) Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol 7(2):161–167
140. Philips T, Robberecht W (2011) Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol 10(3):253–263
141. Pineda-Molina E et al (2001) Glutathionylation of the p50 subunit of NF-kappaB: a mechanism for redox-induced inhibition of DNA binding. Biochemistry 40(47):14134–14142
142. Poole LB, Nelson KJ (2009) Discovering mechanisms of signaling-mediated cysteine oxidation. Curr Opin Chem Biol 12(1):18–24
143. Prinarakis E et al (2008) S-glutathionylation of IRF3 regulates IRF3-CBP interaction and activation of the IFN beta pathway. EMBO J 27(6):865–875
144. Qanungo S et al (2007) Glutathione supplementation potentiates hypoxic apoptosis by S-glutathionylation of p65-NFkappaB. J Biol Chem 282(25):18427–18436
145. Qanungo S et al (2014) N-acetyl-l-cysteine sensitizes pancreatic cancers to gemcitabine by targeting the NFκB pathway. Biomed Pharmacother 68(7):855–864
146. Qian J, Fulton DJR (2012) Exogenous, but not endogenous nitric oxide inhibits adhesion molecule expression in human endothelial cells. Front Physiol 3:3
147. Raftery MJ et al (2001) Novel intra- and inter-molecular sulfinamide bonds in S100A8 produced by hypochlorite oxidation. J Biol Chem 276(36):33393–33401
148. Reinhart PH et al (2011) Identification of anti-inflammatory targets for Huntington’s disease using a brain slice-based screening assay. Neurobiol Dis 43(1):248–256
149. Reisz JA et al (2013) Thiol-blocking electrophiles interfere with labeling and detection of protein sulfenic acids. FEBS J 280(23):6150–6161
150. Rees K et al (2011) Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson’s disease: evidence from observational studies (review). Cochrane Database Syst Rev (11):CD008454. doi:10.1002/14651858.CD008454
151. Reynaert NL et al (2004) Nitric oxide represses inhibitory kappaB kinase through S-nitrosylation. Proc Natl Acad Sci U S A 101(24):8945–8950
152. Reynaert NL et al (2006) Dynamic redox control of NF- kappa B through of inhibitory kappaB kinase beta. PNAS 103(35):13086–13091
153. Rogers J et al (2007) Neuroinflammation in Alzheimer’s disease and Parkinson’s disease: are microglia pathogenic in either disorder? Int Rev Neurobiol 82(07):235–246
154. Rojas J et al (2010) Interferon beta for primary progressive multiple sclerosis (review). Cochrane Database Syst Rev (1):CD006643. doi:10.1002/14651858.CD006643
155. Romero J, Bizzozero O (2011) Intracellular glutathione mediates the denitrosylation of protein nitrosothiols in the rat spinal cord. J Neurosci Res 87(3):701–709
156. Roy A et al (2012) Sodium phenylbutyrate controls neuroinflammatory and antioxidant activities and protects dopaminergic neurons in mouse models of Parkinson’s disease. PloS One 7(6):e38113
157. Sabens Liedhegner EA, Gao X-H, Mieyal JJ (2012) Mechanisms of altered redox regulation in neurodegenerative diseases—focus on S-glutathionylation. Antioxid Redox Signal 16(6):543–566
158. Sahin E et al (2014) Macrophage PTEN regulates expression and secretion of arginase I modulating innate and adaptive immune responses. J Immunol (Baltimore, Md.: 1950) 193(4):1717–1727
159. Saijo K et al (2009) A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 137(1):47–59
160. Sakai J et al (2012) Reactive oxygen species-induced actin glutathionylation controls actin dynamics in neutrophils. Immunity 37:1037–1049
161. Salter MW, Beggs S (2014) Sublime microglia: expanding roles for the guardians of the CNS. Cell 158(1):15–24
162. Sapp E et al (2001) Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol 60(2):161–172
163. Saresella M et al (2014) A complex proinflammatory role for peripheral monocytes in Alzheimer’s disease. J Alzheimers Dis 38(2):403–413
164. Schabbauer G et al (2010) Myeloid PTEN promotes inflammation but impairs bactericidal activities during murine pneumococcal pneumonia. J Immunol (Baltimore, Md.: 1950) 185(1):468–476
165. Schwartz M, Shechter R (2010) Systemic inflammatory cells fight off neurodegenerative disease. Nat Rev Neurol 6(7):405–410
166. Sen N et al (2013) Hydrogen sulfide-linked sulfhydration of NF-kB mediates its anti-apoptotic actions. Mol Cell Biol 45(1):13–24
167. Senftleben U et al (2001) Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science (New York, N.Y.) 293(5534):1495–1499
168. Sengupta R, Holmgren A (2013) Thioredoxin and thioredoxin reductase in relation to reversible S-nitrosylation. Antioxid Redox Signal 18(3):259–269
169. Sengupta R et al (2007) Thioredoxin catalyzes the denitrosation of low-molecular mass and protein S-nitrosothiols. Biochemistry 46:8472–8483
170. Shelton MD, Mieyal JJ (2012) Regulation by reversible S-glutathionylation: molecular targets implicated in inflammatory diseases. Mol Cell 25(3):332–346
171. Shelton MD et al (2009) Glutaredoxin regulates autocrine and paracrine proinflammatory responses in retinal glial (muller) cells. J Biol Chem 284(8):4760–4766
172. Slomiany BL, Slomiany A (2011) Helicobacter pylori induces disturbances in gastric mucosal Akt activation through inducible nitric oxide synthase-dependent S-nitrosylation: effect of ghrelin. ISRN Gastroenterol 2011:308727. doi:10.5402/2011/308727
173. Sofic E et al (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson’s disease. Neurosci Lett 142(2):128–130
174. Soulet D, Cicchetti F (2011) The role of immunity in Huntington’s disease. Mol Psychiatry 16(9):889–902
175. Starke DW, Chock PB, Mieyal JJ (2003) Glutathione-thiyl radical scavenging and transferase properties of human glutaredoxin (thioltransferase). Potential role in redox signal transduction. J Biol Chem 278(17):14607–14613
176. Sullivan DM et al (2000) Identification of oxidant-sensitive proteins: TNF-α induces protein glutathiolation. Biochemistry 39(36):11121–11128. doi:10.1021/bi0007674
177. Sun S-C (2013) Noncanonical NF-kB pathway. Immunol Rev 246(1):125–140
178. Sutherland GT et al (2013) Oxidative stress in Alzheimer’s disease: primary villain or physiological by-product? Redox Rep Commun Free Rad Res 18(4):134–141
179. Suzumura A (2013) Neuron-microglia interaction in neuroinflammation microglia are double-edged sword. Curr Protein Pept Sci 14:16–20
180. Tada S et al (2011) Deleterious effects of lymphocytes at the early stage of neurodegeneration in an animal model of amyotrophic lateral sclerosis. J Neuroinflammation 8(1):19
181. Takeuchi S et al (2010) Induction of protective immunity by vaccination with wild-type apo superoxide dismutase 1 in mutant SOD1 transgenic mice. J Neuropathol Exp Neurol 69(10):1044–1056
182. Tasaki Y et al (2012) Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson’s disease model. Neurosci Lett 521(1):15–19
183. Thom SR et al (2008) Actin S-nitrosylation inhibits neutrophil beta2 integrin function. J Biol Chem 283(16):10822–10834
184. Thom SR et al (2013) Nitric-oxide synthase-2 linkage to focal adhesion kinase in neutrophils influences enzyme activity and β2 integrin function. J Biol Chem 288(7):4810–4818
185. Toohey JI (2012) The conversion of H2S to sulfane sulfur. Nat Rev Mol Cell Biol 13(12):803. doi:10.1038/nrm3391-c1
186. Townsend DM et al (2009) Novel role for glutathione S-transferase pi. Regulator of protein S-glutathionylation following oxidative and nitrosative stress. J Biol Chem 284(1):436–445
187. Träger U, Tabrizi SJ (2013) Peripheral inflammation in neurodegeneration. J Mol Med (Berlin, Germany) 91(6):673–681
188. Turner MR et al (2004) Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis 15(3):601–609
189. Urushitani M, Ezzi SA, Julien J-P (2007) Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 104(7):2495–2500
190. Walden H, Martinez-Torres RJ (2012) Regulation of Parkin E3 ubiquitin ligase activity. Cel Mol Life Sci 69(18):3053–3067
191. Wang J et al (2001) Reversible glutathionylation regulates actin polymerization in A431 cells. J Biol Chem 276(51):47763–47766
192. Wang J, Pan S, Berk BC (2007) Glutaredoxin mediates Akt and eNOS activation by flow in a glutathione reductase-dependent manner. Arterioscler Thromb Vasc Biol 27(6):1283–1288
193. Wild E et al (2011) Abnormal peripheral chemokine profile in Huntington’s disease. PLoS Curr Hungtington Dis 1:1–9
194. Winkler BS, Orselli SM, Rex TS (1994) The redox couple between glutathione and ascorbic acid: a chemical and physiological perspective. Free Radic Biol Med 17(4):333–349
195. Wu DC et al (2002) Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22(5):1763–1771
196. Xiao Q et al (2007) Mutant SOD1(G93A) microglia are more neurotoxic relative to wild-type microglia. J Neurochem 102(6):2008–2019
197. Xing K-Y, Lou MF (2010) Effect of age on the thioltransferase (glutaredoxin) and thioredoxin systems in the human lens. Investig Ophthalmol Vis Sci 51(12):6598–6604
198. Yang H et al (2013) The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. J Leukoc Biol 93(6):865–873
199. Yazdi AS et al (2010) Inflammatory caspases in innate immunity and inflammation. J Innate Immun 2(3):228–237
200. Yu C, Li S, Whorton AR (2005) Redox regulation of PTEN by S-nitrosothiols. Mol Pharmacol 68(3):847–854
201. Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9(11):798–809
202. Yu Y, Smoligovets AA, Groves JT (2013) Modulation of T cell signaling by the actin cytoskeleton. J Cell Sci 126(Pt 5):1049–1058
203. Zhang Y et al (2013) Kinase AKT controls innate immune cell development and function. Immunology 140(2):143–152
204. Zhang D et al (2014) Detection of protein S-sulfhydration by a tag-switch technique. Angewandte Chemie (International ed. in English) 53(2):575–581
205. Zhao W et al (2010) Extracellular mutant SOD1 induces microglial-mediated motoneuron injury. Glia 58(2):231–243